Misoprostol for cervical ripening and labor induction in pregnancies with oligohydramnios.
The efficacy and safety of misoprostol for cervical ripening and labor induction in patients with oligohydramnios was investigated. 57 pregnancies with oligohydramnios and 58 cases with a normal amniotic fluid volume (controls) were enrolled in this prospective trial. All patients received 50 microg of intravaginal misoprostol every 5 h. Primary outcomes were: cesarean section rate; induction to delivery time; oxytocin augmentation; uterine hyperstimulation; meconium passage; fetal heart rate (FHR) changes; fetal distress requiring delivery, and Apgar scores. There were no differences in the mean time to delivery, cesarean section rate, oxytocin augmentation or Apgar scores. The mean induction to delivery time in oligohydramnios and control groups were, 11 h 43 min and 11 h 18 min, respectively (p > 0.05). FHR changes were observed in 26.3% of oligohydramnios group and 32.7% of control group (p > 0.05). There was no statistically significant difference in the cesarean section rate and the uterine hyperstimulation between the 2 groups. These data suggest that misoprostol can be used as an effective agent for cervical ripening and labor induction in pregnancies with oligohydramnios without increasing the risk for perinatal outcome, compared to those with normal amniotic fluid volumes.
Dede
F Suat
FS
Department of Obstetrics and Gynecology, SSK Ankara Maternity and Women's Health Teaching Hospital, Ankara, Turkey. fsdede@yahoo.com
Haberal
Ali
A
Dede
Hulya
H
Sivaslioglu
Akin
A
Arslanpence
Ilhan
I
D000282:Administration, Intravaginal; D000328:Adult; D001034:Apgar Score; D020070:Cervical Ripening / Q000187:drug effects*; D002585:Cesarean Section / Q000706:statistics & numerical data; D005260:Female; D005316:Fetal Distress / Q000453:epidemiology; D005865:Gestational Age; D006340:Heart Rate, Fetal; D006801:Humans; D007751:Labor, Induced / Q000379:methods*; D016595:Misoprostol / Q000009:adverse effects / Q000627:therapeutic use*; D016104:Oligohydramnios; D010120:Oxytocics / Q000627:therapeutic use*; D010121:Oxytocin / Q000008:administration & dosage; D011247:Pregnancy; D011446:Prospective Studies; D012307:Risk Factors; D013997:Time Factors
D010120:Oxytocics; D016595:Misoprostol; D010121:Oxytocin